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While it haslongbeenknown thatIgGprotects mice from avariety of viral infec-
tions, themechanisms bywhichantibody acts in vivo have proved elusive . Two issues
are of particular interest. First, while antibody inhibits central nervous system
(CNS)' infection with a number of viruses, the specific sites at which antibody acts
against neurally spreading viruses have not been defined . Second, the contribution
of systemic antibody (IgG), as opposed to mucosal antibody (IgA), to control of
viral replication in the intestine remains unclear. We are using the mammalian re-
es as a model system to investigate these issues . Our strategy is to use mAbs
ofknown specificity ina viral system with well-defined pathogenesis in order to identify
stages in viral pathogenesis at which antibody acts .
The pathogenesis ofCNS infection after inoculation of neonatal mice with reo-
virus serotype 3 Dearing (T3D) has been studied in detail (reviewed in reference
1) . Afterintramuscular or footpad (FP) inoculation, T3D replicates initially within
skeletal muscle (2). Virus then spreads to theCNS via peripheral nerves using fast
axonal transport (2) . Once within the CNS, T3D infects neurons (3-5) . After in-
tracerebral (IC) inoculation, T3Dreplicates andspreads to the eye to infect the retinal
ganglion cells (6). Both the capacity of T3D for neural spread and its tropism for
neurons are determined by the viral Sl gene (2, 4, 6) which encodes the viral cell
attachment protein to and, in addition, a nonvirion-associated protein (7, 8) .
Reoviruses can produce infection in mice after oral inoculation (9-11). T3D, a
laboratory-adapted virus, has lost the ability to cause lethalCNS infection afterperoral
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(PO) infection (9). However, reovirus serotype 3 clone 9 (T3C9, 12) differs from
T3D in that it is lethal in neonatal mice after PO infection (Hrdy, D. B ., unpub-
lished data), and can be transmitted from infected to uninfected neonatal mice, pre-
route (10). Thus, T3C9 provides a useful model for viruses
such as polio for which neural invasion follows primary enteric infection (13) .
Once in the CNS, both T3D andT3C9 produce a lethal necrotizing meningoen-
cephalomyelitis (3-5, 14) . CNS infection is accompanied by extensive neuronal de-
struction and associated inflammation in cortex, hippocampus, and thalamus . Vari-
ants of T3D that are resistant to the neutralizing almAb produced by the G5
hybridoma (almAbG5, 15) have attenuated neurovirulence (16), and a restricted
pattern ofneuropathologic injury compared with wild-type virus (17) . This provides
additional evidence for the primary role played by the 01 protein in determini
viral neurotropism and neurovirulence .
Thus, previous work has identified several distinct stages in the pathogenesis of
CNS infection with reoviruses : (a) replication at a primary site (skeletal muscle [T3D],
or intestine [T3C9]), (b) spread to the CNS via nerves (T3D) or through as yet
undefined pathways (T3C9), (c) spread and growth of infectious virus within the
CNS, and (d) neuronal destruction and induction of pathology. We have recently
shown that antibody protects neonatal mice from lethal infection with T3D (18) .
Polyclonal rabbit antibody to T3D, neutralizing and nonneutralizing anti-almAbs,
and polyclonal rabbit antibody to determinants other than al all protect mice from
lethal T3D infection . Antibody-mediated protection occurs even after establishment
of extensive CNS infection.
We wished to better understand at which specific stage(s) in the pathogenesis of
T3C9and T3D infection antibody exerts its protective effect. In this paper, we dem-
e that antibody to the al protein : (a) has minimal effect on primary replica-
es such as intestine or muscle, (b) blocks the neural
spread ofT3Dfrom muscle to spinal cord, (c) blocks spread ofvirus from the alimen-
tary tract to CNS following PO inoculation, (d) inhibits spread of infectious virus
within the CNS, (e) inhibits replication within the CNS, and (f) significantly alters
the pattern of T3D induced neuropathology.
Materials and Methods
Animal Inoculations and Tissue Sampling .
￿
Neonatal NIH Swiss [NIH(s)] mice born of preg-
nant mothers obtained from the National Cancer Institute (Frederick, MD) were used in
all experiments . Mice were injected with virus on the day after birth unless otherwise noted .
IC, hindlimb FP, and PO injections were carried out as previously described (9, 18). Unless
otherwise noted all experiments used 100 times the IC LD5o or 100-250 times the FP LD5o
ofT3D in order to assure that the majority of mice would die from viral infecti
absence of antibody administration . The LD5o forT3D in NIH(s) mice is 4.8 logjo plaque-
forming units (PFU) per mouse after FP inoculation, and I loglo PFU/mouse after IC in-
oculation (18) . The expectedmean day ofdeath after receiving these doses ofT3D are 9-10 d
fter IC and 10-12 d after FP inoculation . At various times after infection, mice were killed
and tissues samples including brain, eye, superior and inferior spinal cord (SSC and ISC),
muscle, and intestine (from duodenum to rectum) were collected into 1.0 ml of gel
and frozen at -70°C before assay (18). Antibody or control solutions (100 p.l vol) were in-
jected intraperitoneally as previously described (18) . Either 200 hg ofaffinity-purified oImAbG5,
a 1 :1 dilution of antiT3D serum, or undiluted ascites was used in all experiments. 200 Wg
ofolmAbG5 is fourfold more antibody than would be expected to protect 100% ofmice fromTYLER ET AL.
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FP inoculation with 100 x LD50 of T313 (18). Previous experiments showed that the half-
life of almAbG5 in neonatal mice was >3 d (unpublished data). Unless otherwise noted
pyrogen-free normal saline (PFNS; Travenol Inc., Deerfield, IL) was used for control injections.
Virusand Viral Assays.
￿
Reovirus T3C9 (12), T3D, and variant AN were derived from lab-
oratory stocks. Viruses were doubly plaque purified and then passaged twice on L929 cells.
Second passage virus was used for animal infection. The amount of infectious virus present
in tissues was assayed as previously described (18). Briefly, tissue samples were frozen and
thawed three times (-70'C, 37*C), and then sonicated for 15-30 s. Serial 10-fold dilutions
in gel saline were plated in duplicate on L cell monolayers and overlaid with medium con-
taining agar. After 7 d, plaques were visualized using neutral red (Fisher Scientific, Pitts-
burg, PA). Vial titers are reported as plaque forming units per milliliter. The data in Fig.
1-5, 8, and 9 are presented as the mean and standard error of the mean.
To ensure that neutralizing antibody in tissues from antibody-treated mice did not inter-
fere with our ability to detect infectious virus, we mixed known amounts of T3D with soni-
cated brain tissue from antibody-treated mice, incubated this mixture at 37'C for 60 min,
and then assayed the mixture for infectious virus. Tissue from antibody-treated animals did
not decrease viraltiterin these mixtures (data not shown), demonstratingthat antibody present
in tissue was not responsible for diminution of viral titers in antibody-treated animals.
Production, Purification, andAssay ofAntibodies.
￿
Production, purification, and assay of serum,
ascites, and mAb were performed as previously described (18). Polyclonal antibody to T3D
(antiT3D serum) was raised in rabbits immunized with pure T3D. mAb to the T3D of pro-
tein (almAbG5) was prepared by protein A-Sepharose (PharmaciaFine Chemicals, Piscataway,
NJ) chromatography oftissueculture supernatant from the G5 cell line. almAbG5-containing
ascites was obtained from pristane-primed BALB/c mice (National Cancer Institute, Frederick,
MD) bearing the G5 cell line. G5-containing ascites was equivalent to 144 Rg/ml of purified
o,ImAbG5 by ELISA using purified T3D as antigen (data not shown). Control ascites was
generated using the 8133 cell line that did not produce antibody to T3D (15, data not shown).
Both T313 immune serum and almAbG5 had significant neutralizing activity against T3D
and T3C9 (15, 18, our unpublished data).
Tissue Pathology.
￿
Tissue samples were collected in 10°Jo buffered formalin (Fisher Scientific,
Medford, MA), embedded in paraffin, sectioned, and stained with hematoxylin and eosin.
Slides were examined by K. L. Tyler and H. W. Virgin after covering all identifying signs
and randomizing slides from different experimental groups. Areasofcortex, meninges, hip-
pocampus, and thalamus were separately evaluated, and scored for the presence of necrosis,
inflammation, and viral inclusions.
Results
Efect of oImAbG5 Administered before T3D Infection.
￿
24 h after receiving either
almAbG5 or PFNS IP, mice were inoculated with T3D in the footpad (FP) (Fig.
1). In PFNS-treated mice, virus spread from hindlimb muscle to spinal cord and
brain. Viral titers in the ISC were >3 logto higher than those in the SSC and brain
at day 3, reflecting the neural spread of T3D (2). Pretreatment ofmice with almAbG5
significantly altered the pathogenesis of T3D infection. There was marked inhibi-
tion of the spread of virus from muscle to the CNS (Fig. 1). almAbG5 significantly
(>5 log io at day 10) inhibited spread ofvirus to the ISC and brain. Thus, adminis-
tration of almAbG5 before infection with T3D inhibited both entry of virus into
the ISC, and subsequent spread of virus to SSC and brain.
Effect ofvlmAbG5Administeredat the Same Time as T3D Infection.
￿
Mice were inocu-
lated with T3D in the FP and simultaneously given either almAbG5 or PFNS (Fig.
2). a1mAbG5 inhibited entry of virus into the CNS. Treatment with almAbG5 re-
duced viral titer in both ISC and SSC by 2-5 logio. almAbG5 also inhibited spread
of virus from spinal cord to brain, with viral titers in brain >5 logio lower inCHANISM OF ANTIBODY PROTECTION
0 2
I
almAbG5-treatedanimalsby 5 after infection. Thus, antibody adminsitered simul-
taneous to viral inoculation inhibited entry of virus into, and subsequent spread
within, the CNS.
Effect ofoImAbG5 Administered after Virus has Reached the CNS.
￿
The experiments
above show that antibody present early in infection acts to prevent viral entry into
the CNS. Antibody can also protect mice subsequent to viral entry into the CNS
(18). To define sites of antibody action late in infection, we infected mice with T3D
in the FP and delayed almAbG5 transfer by 24 h (Fig. 3). After the first 48 h, the
amount ofvirus in the ISC ofalmAbG5-treatedanimalsdeclined sharply compared
with controls. In addition, almAbG5 markedly inhibited spread from ISC to SSC
and brain. Similar results were obtained with polyclonal antiT3D serum (datanot
shown). Thus, both monoclonal and polyclonal antibodies to T3D inhibited spread
of virus within the CNS, and decreased virus titer in the ISC.
Effect ofofmAbG5on T3D InfectionofMuscle.
￿
To determinewhetherfailureofvirus
to spread from muscle to ISC wasduesolely to inhibition ofviralreplication in muscle,
we examined the effect of antibody on T3D infection of muscle. almAbG5 was ad-
ministered prior to (Fig. 4 A), at the same time as (Fig. 4 B), or after (Fig. 4 C),
FP infection with T3D. almAbG5 did not significantly alter viral titer in muscle
until late in infection (see day 10, Fig. 4 A).
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FIGURE 1.
￿
Effect of antibody administered be-
fore viral inoculation. Mice were given either
almAbG5 or PFNS IP. 24 hlater mice were in-
oculated withT3Din thehindlimb FP 3and10 d
after infection, samples of ISC, SSC, and brain
were collected andassayed forvirus(three to five
mice perdata point). Only upward errorbars are
shown for clarity. (") 410 PFU/ml.
FIGURE 2.
￿
Effect ofantibody administered
at the time of viral inoculation. Mice were
given either almAbG5 or PFNS IP. At the
same time, mice were inoculated with T3D
in the hindlimb FP At the indicated times
postinfection samplesofISC, SSC, and brain
were collected and assayed for virus (five to
sevenmice perdata point). Only upward error
bars are shown for clarity.
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FIGURE 3.
￿
Effect ofantibody administered
afterviral inoculation. Mice were inoculated
in thehindlimb FPwith T313. 24hlatermice
were given almAbG5-containing or control
(8D3)ascites. At theindicatedtimes, samples
ofISC andSSCandbrainwere collectedand
assayed for virus (two to four mice per data
point). Only upwarderrorbarsareshownfor
clarity.
To assess the effect ofantibody on primary replication in amore sensitive experi-
ment, we inoculated mice with a low dose of T3D (3 logto PFU) into the FP, and
assayed viral titer in the presence and absence ofantibody at a time (day 6) when
viral growth in muscle would be maximal (Tyler, K. L., unpublished data) (Fig-
4 D). There was no significant difference in viral titers between almAbG5 treated
and control muscles.
We conclude that almAbG5-mediated inhibition ofviral entry into and spread
within the CNS, is not due to decrease in viral titerat the primary site ofinfection.
FIGURE 4.
￿
Effect of antibody
on viral titer in muscle. Mice
were infected with T313 in the
FP and at the indicated times
afterinfectionthelegmuscula-
ture was assayed forvirus. (A)
Mice were given almAbG5 or
PFNS IP followed 24 hlaterby
viralinfection (three to five mice
per data point). (B) mice were
givenalmAbG5-containing as-
cites and either control (8133)
ascites or PFNS IP concurrent
with viral infection (5.7 loglo
PFU/mouseinoculated, threeto
nine mice per data point). (C)
Mice were givena1mAbG5con-
taining or control (8133) ascites
24 h after FP infection with
T3D(two to fourmice perdata
point). (D) Mice were given
almAbG5 or PFNS IP 24 h
after footpad infection with
1,000 PFU of T313 (nine mice
per data point). Only upward
errorbars areshownforclarity.892
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Effect of oalmAbG5 after IC Inoculation with TM
￿
To further define the effect of
vlmAbG5 on spread and growth within the CNS, we inoculated mice IC with T3D
and 24 h later administered either almAbG5 or PFNS IP (Fig. 5). In mice given
PFNS, virusreplicated in brain, and spread from brain to eye, SSC, ISC, and hind-
limb muscle. a1mAbG5 almost completely inhibited spread of virus to these sites,
and inhibited viral growth in the brain (Fig. 5).
Effect of trImAbG5 on Neuropathology Produced by TM
￿
To determine the effect of
a1mAbG5 on T313-induced neuropathology we inoculated mice IC with T3D, and
24 h later gave them either almAbG5 IP (n = 36) or no treatment (n = 11). Un-
treated mice were killed when moribund (day 9-10). All animals given almAbG5
appeared healthy, and 16 were killed on days 9-10 for comparison with theuntreated
group. Additional almAbG5-treated mice were killed at day 16-17 (n = 11), and
day 21-22 (n = 9).
By day 9, untreated mice had substantial necrosis of cortex (8/11), hippocampus
(6/9), and thalamus (9/10). Almost allanimalsshowed marked perivascular andmenin-
geal inflammation in the cortex (9/11), hippocampus (7/9), and thalamus (10/10).
In contrast, there was no significant neuronal necrosis in almAbG5-treated mice
(1 of 16 mice had mild cortical and thalamic necrosis). Fig. 6 shows sections of hip-
pocampus on days 9-10 in the presence (A), and absence (B), of aImAbG5 treat-
ment. 2 of 16 almAbG5-treated mice had inclusions within neurons in the hip-
pocampus. At day 9-10, almAbG5-treated mice had evidence of mild perivascular
inflammation, and 6 of 16 mice had mild inflammation, confined primarily to the
perihippocampal area.
olmAbG5-treatedmice killed at 16-17 d after infection had no evidence of either
tissue necrosis or viral inclusions. However, almost all mice had prominent perivas-
cularinflammation involvingthehippocampus(9/11, Fig. 7 B), and thalamus (6/11),
but completely sparing the cortex (0/11). Similarly, 9 of 11 mice showed significant
perihippocampal meningeal inflammation (Fig. 7 B). This inflammatory response
was still present on day 22, and was accompanied in some mice by hippocampal
necrosis (4/9).
Thus, a1mAbG5 eliminated neuronal necrosis and significantly attenuated the
initial T313-induced inflammatory response. A prominent inflammatory response
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Effect ofantibody administered
after IC inoculation. Mice were inoculated
with 3logloPFUofT3DIC. 24 hlatermice
received either almAbG5-containing ascites
or PFNS IP At the indicatedtimes, samples
ofbrain, eye, ISC, SSC, andmuscle were col-
lected andassayed forvirus(controls: two to
three mice mice per data point; antibody-
treated: five to seven mice per data point).
Only upward errorbars are shown forclarity.TYLER ET AL .
￿
893
FIGURE 6.
￿
Effect of antibody on neuropathology induced by T3D . Mice were inoculated with
3 logloPFU ofT3D IC. 24 h later mice were given either no treatment or either almAbG5 or
PFNS IP Photomicrographs ofcoronal brain sections stained with hematoxylin and eosin are
shown(original magnification, x 100). (A)Day 10, almAbG5 treatment. (B)Day 10, PFNS treat-
ment . HC, hippocampus ; M, meninges ; T, thalamus.
did appear by day 16 in olmAbG5-treated animals and gradually waned over the
ensuing week. This late inflammatory response was limited almost entirely to the
perihippocampal region, and was associated with some delayed neuronal necrosis .
Absence of Detectable olmAbG5-resistant Variants In Viva
￿
The neuropathology ob-
served in both olmAbG5-treated mice and mice infected witholmAbG5 mAb-resistant
(mar) variants ofT3D is restricted to the limbic system (17) (Fig. 7) . To determine894
￿
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FIGURE 7 .
￿
Effect of antibody on late neuropathology induced byT3D . Mice were inoculated
with either 3 logloPFU ofT3Dor 6.3 logo PFU of variant AI7 IC . 24 h later mice were given
either almAbG5 IP or left untreated. Photomicrographs of coronal brain sections stained with
hematoxylin and eosin are shown (original magnification, x 100). (A) Day 10, variant AN in-
fected given no treatment . (B) Dray 16,T3D infected giveno1mAbG5 treatment . HC,hippocampus;
M, meninges, T, thalamus .
whether antibody treatment resulted in the selection of mar mutants in vivo, we
studied 40 doubly plaque-purified viral isolates from brains of almAbG5-treated
mice obtained 9-10 d after infection . We found that all isolates (40/40) remained
sensitive to neutralization withaconcentration ofaImAbG5 (1 Rg/ml) that neutralizes
T3D, but not variants selected using aImAbG5 (datanot shown, 15, 16, 18) . Thus,
the small amounts of virus detected in brains ofalmAbG5-treated animals 9-10 d
after inoculation presumably represent wild-typeT3D virus that escaped antibody
blockade, and not in vivo selected mar mutants .
Effect ofalm&G5 on the Pathogenesis ofT3C9 Infection .
￿
T3C9 is a serotype 3 reo-
virusthat produces encephalitis afterPO infection, providing a model for studying
the effect of systemic antibody on CNS infection produced after viral entry via the
gastrointestinal tract . Mice were inoculated PO with 7 logto PFU ofT3C9, and 24 h
later were givenPFNS, almAbG5, or anti-T313 serumIP All mice (n = 12) receiving
PFNS died after a mean of 10.4 t 1 .5 d. In contrast, none of the mice receiving
aImAbG5 (n = 11), or anti-T31) serum (n = 12) died over a 30-d period.
To study the effect ofantibody on spread ofT3C9 to theCNS afterthe establish-
ment of intestinal infection, mice were inoculated with 7 logto PFU ofT3C9 PO
and 24 h later were given PFNS or almAbG5 IP (Fig. 8) . almAbG5 blocked T3C9
viremiaandcompetely inhibitedentry ofT3C9 into spinal cordand brain, butonly
slightly reduced T3C9 titer in intestine (day 9) .1o
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We next assessedthe roleofantibody administered before POinfectionwith T3C9
(Fig. 9). Mice were given either almAbG5 orPFNS IP, and 24h later were inocu-
lated with 6.41oglo PFU ofT3C9 PO. almAbG5 prevented entry of T3C9 into the
CNS without reducing the amount ofvirus in intestinal tissue (Fig. 9 B). To assess
the influence ofantibody on intestinal primary replication in a more sensitive ex-
periment, mice were inoculated PO with 2.8 logto PFU of T3C9 IP 24 h after
receiving either almAbG5 or PFNS IP (Fig. 9 A). almAbG5 had no effect ofpri-
mary replication and yet completely blocked the spread ofvirus from the intestine
to the CNS.
Thus, antibody protects mice from lethal PO infectionwith a serotype 3 reovirus.
This protection involves prevention of spread ofvirus from the intestinal primary
site to the CNS in the absence ofany effect on growth ofvirus at the primary site.
Discussion
In this paper we define stages at which an IgG mAb specific for the reovirus cell
attachment protein a1 acts toprotectmiceagainstlethal reovirus-inducedCNS dis-
ease (see Fig. 10). Antibody inhibited entry ofvirus into the CNS from extraneural
sites ofprimary replication(eithermuscle or intestine), buthadonly minimaleffects
on viral replication at these sites. Antibody administered after virus had already
FIGURE 8. Effect of antibody ad-
ministered after PO inoculation with
T3C9. Mice were inoculated with 7
loglo PFU of T3C9 PO. 24 h later
mice received either almAbG5 or
PFNS IP At the indicated times
samples of intestine, ISC and SSC,
brain, andbloodwere collectedandas-
sayed for virus (three mice per data
point). Only upward error bars are
shown for clarity. (") < 10 PFU/ml.
FIGURE 9.
￿
Effect of antibody administered
before PO inoculationwithT3C9. Micewere
giveneither almAbG5or PFNS IP 24 hlater
mice were inoculated with either 2.8 loglo
PFU (A), or 6.4 loglo PFU (B) of T3C9 IP.
At the indicated times, samples of intestine
andbrainwere collectedand assayed forvirus
(fourto sevenmice perdata point). Only up-
ward errorbars areshownforclarity. (")<10
PFU/ml.896
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FIGURE 10 .
￿
Sites of antibody action . (1) Anti-
body has minimal effects on viral titer in muscle
early after infection. (2) Antibody inhibits spread
of virus from muscle to inferior spinal cord . (3)
Antibody blocks entry into and/or growth within
the inferior spinal cord. (4) Antibody blocks
spread ofvirus from inferior spinalcord to supe-
rior spinal cordand brain . (5) Antibody inhibits
growth ofvirus in thebrain, and limits pathology
to the hippocampus and perihippocampal tissues .
(6) Antibody blocks spread from brain to eye . (7)
Antibody blocks spread of virus from the intes-
tine to brain and spinal cord. (8) Antibody has
no effect on primary replication in the intestine .
invaded the CNS, prevented subsequent growth and spread of virus . Antibody also
prevented the development of necrotizing cortical encephalitis and limited T3D-
induced pathologic changes to the limbic system .
Effect ofAntibody at thePrimary Site ofInfection .
￿
Although for some viral infections
antibody-mediated inhibition of entry into theCNS is accompanied by inhibition
ofprimaryreplication (19), this is not invariably true . Forexample, neither immuni-
zation with killed poliovirus vaccine norpassive transfer of antibody eliminates gas-
trointestinal shedding of poliovirus, yetboth clearly protect againstthedevelopment
of paralytic poliomyelitis (20-24) . In contrast, immunity established after immuni-
zation with Sabin oral poliovirus vaccine, or following recovery from natural infec-
tion with polovirus, results in both protection from CNS disease anddecreasedshed-
ding of virus from the intestine (20, 25) . These results have been used to argue that
local immunity, rather than systemic IgG, plays a predominant role in limiting viral
shedding from the alimentary tract, although a role for systemic antibody has also
been suggested (21, 26) . Our studies clearly show that although systemic IgGmay
be extremely effective in preventing viral spread to the CNS, even a high dose of
protective IgG has no effect on replication of virus in the intestine .
Effect ofAntibody on Entryof Virus into the CNS .
￿
T3D spreads from muscle to CNS
vianerve, a capacity conferredby the T3 Sl gene (2) encoding the outercapsid pro-
tein al . almAbG5 given before, or at the same time as, infectionwithT3D inhibited
entry of virus into the CNS (Figs . 1 and 2 ; Fig . 10, site 2), without significantly
decreasing viral titer in muscle (Fig. 4; Fig. 10, site 1), clearly showing that IgG
can inhibit spread of virus through nerves . Antibody inhibits entry of herpes virus
into theCNS (19), and prevents the development of paralytic poliomyelitis after in-
oculationof neurally spreadingpoliovirus stains (27), providingadditional examples
of inhibition of neural spread (Fig. 10, site 2).
Effect ofAntibody on Growth andSpread within theCNS
￿
Antibody protects mice afterTYLER ET AL.
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significant CNSinfectionwith T3Dhas been established(18), indicating that antibody-
mediatedprotection must involve mechanisms inaddition to inhibition ofviral entry
into the CNS. We now show that olmAbG5 inhibited both growth and spread of
virus within the CNS (Figs. 2, 3, 5). Similar phenomenahave been seen with other
neurotropic viral infections (28-32). Thus, inhibition of viral growth and spread
within CNStissue (Fig. 10, sites 3-6) isan importantmechanismofantibody-mediated
protection against neurotropic viral infection.
Effect ofAntibody on Virus-inducedPathology.
￿
Studieswith severalviruses have shown
that antibody can either prevent or alter the nature ofvirally induced tissue injury
(33-35). In our experiments, almAbG5-treated animals had several major altera-
tions in CNS pathology (Figs. 6 and 7). There was marked reduction and delay in
tissue injury, and in the appearance ofT313-induced inflammatory responses. The
inflammatory response, when present, wastopologically restricted to perihippocampal
tissues.
There are several possible explanations for the restricted pattern of injury and
inflammation seen in our experiments. First, the cells in the hippocampus may be
more vulnerable to injury by T3D or G5-selected variants than cortical neurons.
A similar selective vulnerability ofthe hippocampus has been seen following a va-
riety of CNS insults including hypoxia (36). Second, the hippocampus may be the
site ofearlyreplication for T3D afterIC inoculationandantibody mayinhibit spread
of virus from this site to distant regions such as cortex. Finally, it is possible that
a determinant on the of protein is critical to causing cortical injury and this deter-
minant is lackingin G5-selected variants ofT3D, or directly inhibited by oImAbG5
in vivo.
MechanismofAntibody Action at DefinedStages in Pathogenesis.
￿
In this study we have
defined specific pathogenetic stepsat which antibody acts to protect mice from CNS
infection. The precise mechanism(s) by which antibody acts at these steps are not
understood. A role forcomplement, antibody-dependent cell-mediatedcyctotoxicity,
or the Fc portion ofIg has been proposed but never unequivocally documented in
vivo (reviewed in reference 18). Alternatively, it has been assumed that the action
ofantibody in vivo isrelated to invitro functions such as neutralization (i.e., plaque
reduction). A lack ofcorrelation between in vitro neutralization and protection has
been repeatedly demonstrated fora wide variety ofviral infections (reviewed inref-
erence 18), clearly indicating that in vivo protection is not simply an analogue of
in vitro neutralization. Studies limited to antibodies that are "neutralizing" in vitro
may not be relevant to understanding protective immune responses in vivo. Simi-
larly, vaccine development strategies based on the induction ofneutralizing anti-
body may not lead to protection of the host.
Another possible mechanism for the prevention of neural spread and protection
provided by o1mAbG5 is inhibition ofcritical in vivo functions ofthe of molecule
such as attachment ofT3D to neurons (4), or spread within nerves (2). In rats, the
S1 gene determines the pattern ofclearance of reovirus Tl from the blood stream
after intravenous inoculation, and antibody tothe TI of protein alters this clearance
(37). This suggests that antibody to the TI of protein may alter the pathogenesis
ofTI infection by binding to and inhibiting the normal function of a viral capsid
protein.
Antibody could also be acting at intracellular sites to inhibit key steps in the life898
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cycle of the virus or the movement of the virus within cells (38, 39). Antibody has
been demonstrated inside nerve cells afterpassive transfer (40), and couldtherefore
act at this site to prevent viral growth or spread. These observations suggest that
antibody may act across thecell membrane, or within neural cells, to inhibit critical
steps in viral replication or assembly.
Furtherwork will be needed to define thespecific mechanisms by whichantibody
acts at defined sites in the pathogenesis of CNS infection. We are currently charac-
terizing a panel of mAbs to capsid proteins other than a1 in order to study similari-
ties or differences in the in vivo sites of action of these antibodies compared with
sites identified in this paper for a mAb to the al protein. In addition, the fact that
immune cells also protectfrom lethal infection with T3D and T3C9 (Virgin, H. W.,
and K. L. Tyler, unpublished data) opens up the possibility that we will be able
to define and contrast the specific sites at which cells and antibody act to combat
viral infection.
Summary
The mammalian reoviruses provide a model for studying specific aspects of the
immunopathogenesis of viral infection. We have used two serotype 3 reoviruses to
define stages in the pathogenesis ofcentralnervous system (CNS) infection at which
a mAb specific forthe reoviral cell attachment protein al (almAbG5) acts to protect
mice against lethal disease. almAbG5 administered either before or at the time of
footpad inoculation with reovirus T3D prevented entry of T3D into the CNS.
almAbG5 also inhibited the spread of reovirus T3C9 from the gastrointestinal tract
to the CNS after peroral inoculation with T3C9. These effects occurred in the ab-
sence of a significant effect of almAbG5 on primary replication in skeletal muscle
(T3D) or the gastrointestinal tract (T3C9). a1mAbG5 administered after T3D had
reached the spinal cord inhibited subsequent spread of infectious virus from spinal
cord to brain. Even afterdirect intracerebralinoculation ofT3D, almAbG5 prevented
both growth in the brain and spread of infectious virus from brain to eye, spinal
cord, and muscle. Treatment with almAbG5 after intracerebral inoculation with
T3D prevented neuronal necrosis and resulted in adelayed and topographically re-
stricted inflammatory response. We detected no antibody-resistant T3D variants in
vivo after treatment with almAbG5. We conclude that systemic IgG does not play
a significant role at the primary site of infection with reoviruses, while it clearly acts
to prevent infection of the CNS and extension of infection with the CNS. Further
study will be directed to defining what components of the immune system do act
at primary sites of infection, and to defining the mechanisms by which antibody
acts at defined stages in pathogenesis.
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